Tiziana Life SciencesLife Sciences has submitted an Investigational New Drug (IND) application to the FDA for a phase 2 clinical trial of intranasal foralumab for Amyotrophic Lateral Sclerosis (ALS). This application follows a grant award from the ALS Association’s Hoffman ALS Clinical Trial Awards Program, supporting Tiziana’s focus on intranasal foralumab for three neurodegenerative diseases: ALS, Multiple Sclerosis, and Alzheimer’s disease. The grant fosters collaboration between industry and academia to translate research into clinical studies.
This IND submission is a crucial step in developing new treatment options for ALS, a fatal neurodegenerative disease with limited effective therapies. A phase 2 trial will provide critical data on the safety and potential efficacy of intranasal foralumab, offering hope to patients facing a devastating diagnosis with a currently poor prognosis. The study will evaluate how well foralumab can slow disease progression and improve quality of life. This trial will also generate data that can inform further research and development into much needed therapies for ALS.
The planned phase 2 trial will involve 20 patients and assess two doses of intranasal foralumab. Foralumab, a fully human anti-CD3 monoclonal antibody, is designed to stimulate T regulatory cells when administered intranasally. Previous studies have shown promising results with foralumab in other neurological conditions, including Multiple Sclerosis, suggesting its potential to modulate the immune system and impact neurodegenerative processes. The company has ongoing Expanded Access programs and clinical trials exploring foralumab in other neurological indications.
The initiation of this clinical trial represents a significant step toward potentially improving treatment outcomes for ALS. Positive results could pave the way for larger studies and ultimately bring a novel therapeutic option to patients suffering from this debilitating disease. Further, this reinforces the potential of intranasal foralumab as a platform technology for addressing a range of neurodegenerative disorders.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
